Prof Jennifer Knox speaks to ecancer at ASCO 2024 about early results of the PASS-01 trial, which evaluates the benefit of 1st line modified FOLFIRINOX versus gemcitabine/nab-paclitaxel in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

She explains that the idea behind the trial was to understand whether there are any biomarkers that can be identified early on in the diagnosis of metastatic pancreas cancer and use this to inform treatment after standard-of-care chemotherapy.

Prof Knox reports that very little difference was seen between the chemotherapy regimens and the unimpressive performance of both highlights the importance of precision treatment and adding novel therapies into the mix.